Neurology
Conference Coverage
Ladostigil advances to phase III after hints of slowing brain atrophy in MCI patients
SAN DIEGO – Ladostigil, a drug that combines molecular characteristics of rivastigmine and rasagiline, was associated with modest memory...
Conference Coverage
First visit for tuberous sclerosis complex comes months before diagnosis
HOUSTON – Many patients who eventually receive a diagnosis of tuberous sclerosis complex present with related complaints for months, or even years...
News from the FDA/CDC
Latest CDC data: Opioid deaths still rising
The U.S. death rate from synthetic opioids, including fentanyl, soared by 72.2% from 2014 to 2015, according to the CDC.
Conference Coverage
Phase I results move Alzheimer’s candidate drug aducanumab into phase III trials
SAN DIEGO
News from the FDA/CDC
FDA warning: General anesthetics may damage young brains
FDA warning says repeated or lengthy use of general anesthetic or sedation drugs under age 3 years or in late pregnancy may affect children’s...
From the Journals
Lack of natalizumab concentration increase before PML argues against extending dosing interval
Serum concentrations of natalizumab do not appear to rise before patients with relapsing-remitting multiple sclerosis are diagnosed with...
Conference Coverage
Sigma-1 agonist presses forward after positive results in small Alzheimer’s trial
SAN DIEGO
Conference Coverage
Cardiovascular comorbidities common in patients with epilepsy
HOUSTON – Adults with epilepsy reported five of the six most common cardiovascular diseases more often than did adults without epilepsy, according...
From the Journals
Two-test sequence identifies sporadic Creutzfeldt-Jakob with 100% sensitivity, specificity
The sequential use of two diagnostic tests – one assessing cerebrospinal fluid and the other assessing nasal swabs – identifies sporadic...
Conference Coverage
TauRx still rooting for its methylene blue AD drug, despite controversial study results
SAN DIEGO – An anti-tau compound that has stirred scientific controversy for 8 years will continue along its developmental pathway at a much lower...
Conference Coverage
After full data release, experts say failed Alzheimer’s trial EXPEDITION 3 offers hopeful signals
SAN DIEGO – Solanezumab may have not have slowed the relentless march of Alzheimer’s disease, but it was a valuable proving ground of the amyloid...